In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis

The peptide hormone human relaxin-2 (H2-RLX) has emerged as a potential therapy for cardiovascular and fibrotic diseases, but its short in vivo half-life is an obstacle to long-term administration. The discovery of ML290 demonstrated that it is possible to identify small molecule agonists of the cog...

Descripción completa

Detalles Bibliográficos
Autores principales: McBride, Andrew, Hoy, Anna M., Bamford, Mark J., Mossakowska, Danuta E., Ruediger, Martin P., Griggs, Jeremy, Desai, Sapna, Simpson, Kate, Caballero-Hernandez, Ivan, Iredale, John P., Pell, Theresa, Aucott, Rebecca L., Holmes, Duncan S., Webster, Scott P., Fallowfield, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589886/
https://www.ncbi.nlm.nih.gov/pubmed/28883402
http://dx.doi.org/10.1038/s41598-017-10521-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589886/
https://www.ncbi.nlm.nih.gov/pubmed/28883402
http://dx.doi.org/10.1038/s41598-017-10521-9

Ejemplares similares